Amira Nature Foods Ltd. (NYSE:ANFI)
ANFI reported strong financial results, reflecting its ability to consistently add new customers in India and internationally, enter new markets as well as the continued growing demand for its premium product offerings.
On its second quarter fiscal 2014, ANFI posted revenue of $108.0 million, a 36.1% increase year over year, and profit after tax of $6.3 million, a 90% increase compared to $3.3 million in the same period the prior year.
ANFI reiterates its previously issued guidance and continues to expect full year fiscal 2014 revenue in the range of $480 million to $507 million and EBITDA in the range of $62 million to $66 million (based on foreign exchange rates as of September 30, 2013). This is in line with long-term guidance previously provided to the investment community in connection with ANFI ’s initial public offering.
Shares of ANFI closed at $14.80 on Monday's trading session.
ANFI sells Basmati rice, a premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. ANFI sells its products primarily in emerging markets through a broad distribution network.
More about Amira Nature Foods Ltd. (NYSE:ANFI) at www.amirafoods.com .
**
Crown Equity Holdings Inc. (CRWE)
CRWE has updated its membership driven online e-commerce venture business plan. The name of the business will be known as “iB2B Global”.
Looking to deliver value for its stockholders in both the near and long term, CRWE is targeting the multi-billion dollar B2B Industry with its iB2B Global project. While the sheer number of retail transactions throughout the globe on a daily basis is of course larger, the money flow created in B2B is formidable due to the size of the transactions.
CRWE ‘s iB2B Global mission is to make it easy for anyone to buy or sell anywhere in the world.
As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
**
MediciNova, Inc. (Nasdaq:MNOV)
Irritable bowel syndrome is a functional gastrointestinal disorder; it causes cramping, abdominal pain, bloating gas, diarrhea and constipation.
Irritable bowel syndrome is estimated to affect 10 to 15 percent of the population.
MNOV reported that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome.
The new patent (U.S. Patent No. 8,518,995) will expire no earlier than April 2031. The claims cover a method for treatment of irritable bowel syndrome using certain compounds including MN-221. The claims cover various routes of administration including oral, injectable and transdermal.
MNOV stock closed at $2.17, representing an increase of $0.02 (or +0.93%).
MNOV is a biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market.
More about MediciNova, Inc. (Nasdaq:MNOV) at www.medicinova.com .
**
Read Full Disclaimer at www.drstockpick.com/disclaimer
